P2Y2 receptor activation promotes esophageal cancer cells proliferation via ERK1/2 pathway

Esophageal cancer is a prominent worldwide illness that divided into two main subtypes: esophageal squamous cell carcinoma and adenocarcinoma. Mortality rates are alarming, the understanding of mechanisms involved in development, becomes essential. Purinergic signaling related to many diseases among these various types tumors. Here we studied effects P2Y2 receptor activation different cancer. tissue samples healthy controls were used for P2Y2R expression quantification. Two human lines Kyse-450 (squamous carcinoma) OE-33 (adenocarcinoma) perform vitro analysis proliferation, migration, adhesion, pathways activation. Data showed was expressed biopsies patients with ESCC adenocarcinoma, as well studied. The RT-qPCR demonstrated cells have higher P2RY2 than line. Results activation, induced by ATP or UTP, promoted proliferation colony formation. blockage selective antagonist, AR-C 118925XX, led decreased formation adhesion. Treatments UTP activated ERK 1/2 pathway ECA cells. antagonism did not alter migration Interestingly, presented distinct profile nucleotide hydrolysis activity. modulation receptors may be promising target treatment.